The FDA has expanded approval of the drug Dupixent, originally used for skin and lung disorders, to include treatment for chronic obstructive pulmonary disease (COPD), a lung condition common in smokers. Dupixent is the first biologic therapy approved for COPD, targeting inflammation in the lungs. The drug has shown significant reductions in COPD exacerbations in clinical trials. Developed by Sanofi and Regeneron, Dupixent has seen significant sales growth and is now approved to treat six different conditions. Other biologic therapies for COPD are also emerging, indicating a shift in treatment options for the disease.
Source link
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
